AP
SAGE

AlpInvest Partners’s Sage Therapeutics SAGE Stock Holding History

AlpInvest Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-105,000
Closed -$3.16M – 20
2016
Q2 		$3.16M Buy
105,000
+26,359
+34% +$879K 6.27% 5
2016
Q1 		$2.52M Hold
78,641
– – 4.81% 5
2015
Q4 		$4.58M Sell
78,641
-15,100
-16% -$748K 7.62% 4
2015
Q3 		$3.97M Buy
93,741
+30,000
+47% +$1.85M 7.81% 5
2015
Q2 		$4.65M Buy
63,741
+51,546
+423% +$3.31M 5.89% 8
2015
Q1 		$613K Buy
+12,195
New +$524K 1.15% 18

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AlpInvest Partners's SAGE Position: Q3 2016 in Review

AlpInvest Partners sold out of Sage Therapeutics (SAGE) in Q3 2016, closing a stake of 105,000 shares — an estimated $3.16M sold.

AlpInvest Partners first reported a position in SAGE in Q1 2015 and held it in 6 quarters. The position peaked at $4.65M in Q2 2015. 154 funds tracked by Wall St. Rank hold SAGE as of Q3 2016.

  • AlpInvest Partners reported no remaining Sage Therapeutics position as of Q3 2016 after selling out during the quarter.
  • AlpInvest Partners sold 105,000 Sage Therapeutics shares in Q3 2016, an estimated $3.16M.
  • AlpInvest Partners first reported a position in Sage Therapeutics in Q1 2015 and held it in 6 quarters.
  • AlpInvest Partners's Sage Therapeutics position peaked at $4.65M in Q2 2015.
  • 154 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2016.

Based on AlpInvest Partners's 13F filing for Q3 2016, filed 14 Nov 2016.